findmyKOL
Clinical trialNCT03800134Active, not recruitingPhase 3Interventional

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

SponsorAstraZenecaEnrollment825Non-Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

231 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina
  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Pergamino, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Salvador de Jujuy, Argentina

  • Research Site

    Viedma, Argentina

Austria
  • Research Site

    Graz, Austria

  • Research Site

    Innsbruck, Austria

  • Research Site

    Rankweil, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

Belgium
  • Research Site

    Ghent, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Mons, Belgium

Brazil
  • Research Site

    Barretos, Brazil

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Campinas, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Natal, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Santa Maria, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Teresina, Brazil

  • Research Site

    Vitória, Brazil

Bulgaria
  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

Canada
  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Kitchener, Ontario, Canada

  • Research Site

    Lévis, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Saskatoon, Saskatchewan, Canada

191 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Cisplatin →Durvalumab →Gemcitabine →Paclitaxel →Pemetrexed →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Dec 2018
Primary completion
10 Nov 2022
Completion
11 Sept 2028
Last update posted
11 Jun 2025
Registered enrollment
825
Registry id
NCT03800134

Cross-registrations

EU-CTR / CTIS (EudraCT)2018-002997-29
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.